v3.25.4
OTHER (INCOME)/EXPENSE, NET (Tables)
 12 Months Ended
Dec. 31, 2025
Other Nonoperating Income (Expense) [Abstract]  
Schedule Of Other Income Expense
 Year Ended December 31,
Dollars in millions202520242023
Interest expense$1,891 $1,947 $1,166 
Royalty income - divestitures (Note 4)(1,129)(1,104)(862)
Royalty and licensing income (Note 4)(1,093)(736)(1,488)
Investment income(586)(478)(449)
Provision for restructuring (Note 6)563 635 365 
Litigation and other settlements(a)
434 84 (390)
Loss on debt redemption (Note 10)
356 — — 
Contingent consideration (Note 9)
351 — — 
Equity investment (gains)/losses, net (Note 9)
(280)(16)160 
Integration expenses (Note 6)147 284 242 
Acquisition expense
9 50 32 
Other(b)
11 227 66 
Other (income)/expense, net
$674 $893 $(1,158)
(a)    In 2025, the balance reflects charges related to a pricing, sales and promotional practices dispute and a securities litigation matter. In 2023, the balance includes: (i) $384 million of income related to the settlement of claims in the CTLA-4 litigation with AstraZeneca and (ii) $400 million of income related to the change of control provision under the Nimbus TYK2 inhibitor arrangement, partially offset by (iii) $322 million of expense related to the termination and settlement of disputes with BeiGene, Ltd.
(b)    Includes pension settlement charges of $119 million in 2024 incurred in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan.